Randomized, Open-label, Multi-centered Study to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia(Phase 4)
Phase of Trial: Phase IV
Latest Information Update: 12 Mar 2018
Price : $35 *
At a glance
- Drugs Pitavastatin (Primary)
- Indications Hyperlipidaemia; Prediabetic state
- Focus Therapeutic Use
- Acronyms SIPHON
- Sponsors JW Pharmaceutical
- 31 Aug 2018 Biomarkers information updated
- 06 Mar 2018 Status changed from active, no longer recruiting to completed.
- 08 Mar 2017 Planned End Date changed from 1 Aug 2015 to 1 Oct 2017.